Larazotide dosing & administration
Restore your intestinal barrier and protect against gluten damage
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Oral: Taken by mouth as a capsule, tablet, or liquid.
Bioavailability Varies by compound — many peptides are largely broken down in the gut, so little reaches the blood intact; some small molecules absorb well.
0.5 mg
Frequency
Three times daily (before meals)
Duration
12 weeks in trials; ongoing for symptom control
Trial-established dose: in a Phase 2b randomized controlled trial in celiac disease, 0.5 mg three times daily met the primary endpoint with fewer symptoms vs placebo. Notably, the higher 1 mg and 2 mg doses showed no benefit over placebo, so 0.5 mg is the effective dose [6]. Taken before meals as a local intestinal tight-junction regulator [1].
Timing
Best time to take
Take Larazotide at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
With food?
Larazotide can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
If stacking
Larazotide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Larazotide is administered Oral (capsule or tablet)—no injection required
Best sites
Storage
Before reconstitution
Store Larazotide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Larazotide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Oral (capsule or tablet)—rotate sites if applicable
Maintain a consistent schedule for optimal results with Larazotide. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Headache, Nausea, Abdominal Cramping, Fatigue
Less common: Transient Diarrhea
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Larazotide
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Larazotide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- High-dose NSAIDs — Can increase intestinal permeability and may counteract larazotide's barrier-protective effects
- Excessive Alcohol — Alcohol damages tight junctions and can undermine larazotide's therapeutic benefits
- Certain Antibiotics — May disrupt beneficial gut microbiota needed for barrier healing synergy
Published research
What the studies show
Hoilat GJ, et al. · 2022
Meta-analysis of four randomized trials showed larazotide significantly improved gastrointestinal symptoms when patients were exposed to gluten. The peptide maintained a favorable safety profile with few adverse events, supporting its potential as adjunct therapy.
Damianos JA, et al. · 2026
Larazotide acetate acts as a zonulin antagonist to restore intestinal barrier integrity in celiac disease. The review highlighted larazotide and other barrier-restoring therapies as important complementary approaches to gluten avoidance.
Karahan D, et al. · 2024
Larazotide reduced intestinal damage scores and bacterial translocation frequency from 100% to 50% in acute pancreatitis models. The peptide's tight junction-regulating effects prevented harmful bacteria from crossing the intestinal barrier.
D'heedene MD, et al. · 2024
Larazotide represents a new pharmacological treatment option for celiac disease patients with persistent symptoms. The peptide offers potential to improve quality of life beyond traditional gluten-free dietary management.
Kulkarni A, et al. · 2021
Larazotide emerged as a leading tight junction regulator with robust clinical trial data. The peptide's mechanism of blocking zonulin receptors offers a novel therapeutic approach distinct from traditional gluten-degrading enzymes.
Leffler DA, Kelly CP, Green PHR, et al. · 2015
In 342 adults with celiac disease on a gluten-free diet, larazotide acetate 0.5 mg three times daily met the primary endpoint with fewer symptoms vs placebo; the 1 mg and 2 mg doses showed no benefit over placebo.
Head to head
Larazotide compared
Studied for
Conditions Larazotide has been researched in
Want the full picture?
The complete Larazotide research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.